The platform enables direct, unbiased genome-wide identification and quantification of the exact position of double strand DNA breaks in edited cells.

Akribion Therapeutics emerges from stealth with €8 million in seed funding to develop a novel cancer RNA-guided approach ...

Precision BioSciences, Inc. , a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies, including gene elimination, gene ...

About Precision BioSciences, Inc. Precision BioSciences, Inc. is a clinical stage gene editing company dedicated to improving life (DTIL) with its novel and proprietary ARCUS® genome editing ...

Report with the AI impact on market trends - The global genomics market size is estimated to grow by USD 5.21 billion from 2024-2028, according to Technavio. The market is estimated to grow at a CAGR ...

Colossal BioSciences has raised $200 million in a new round of funding to bring back extinct species like the woolly mammoth.

Genesis announced that it has completed its second successful human transplant with a genetically engineered pig kidney, with ...

A team of stem cell scientists have successfully used embryonic stem cell engineering to create a bi-paternal mouse—a mouse ...

Advances in CRISPR technologies promise to accelerate the burgeoning pipeline of gene-editing therapies and broaden access to these disease-altering therapies.

The recently developed genome-editing technology CRISPR-Cas9 ... My study on these novel mtDNA editors, known as αDdCBEs, will facilitate the generation of new strategies to correct common pathogenic ...

Recent advancements in genome sequencing and genome-wide association ... and the application of gene editing in preterm research, and present novel evidence and strategies for the prevention, ...